Enzon Pharmaceuticals, Inc. (ENZN)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.04 Million USD | -1.32% |
| 2022 | 1.05 Million USD | -9.57% |
| 2021 | 1.17 Million USD | -13.78% |
| 2020 | 1.35 Million USD | 15.0% |
| 2019 | 1.18 Million USD | 11.01% |
| 2018 | 1.06 Million USD | -22.47% |
| 2017 | 1.37 Million USD | -18.34% |
| 2016 | 1.67 Million USD | -21.91% |
| 2015 | 2.15 Million USD | -9.78% |
| 2014 | 2.38 Million USD | -79.38% |
| 2013 | 11.55 Million USD | -67.26% |
| 2012 | 35.3 Million USD | -39.66% |
| 2011 | 58.5 Million USD | -30.7% |
| 2010 | 84.41 Million USD | -37.26% |
| 2009 | 134.54 Million USD | 3.44% |
| 2008 | 130.06 Million USD | 301.59% |
| 2007 | 32.38 Million USD | -71.6% |
| 2006 | 114.03 Million USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 103.54 Million USD | -9.87% |
| 2003 | 114.88 Million USD | 227.18% |
| 2002 | 35.11 Million USD | 41.32% |
| 2001 | 24.84 Million USD | 16.44% |
| 2000 | 21.33 Million USD | 42.26% |
| 1999 | 15 Million USD | 0.0% |
| 1998 | 15 Million USD | 6.38% |
| 1997 | 14.1 Million USD | -22.53% |
| 1996 | 18.2 Million USD | -19.82% |
| 1995 | 22.7 Million USD | -29.5% |
| 1994 | 32.2 Million USD | -8.52% |
| 1993 | 35.2 Million USD | -4.61% |
| 1992 | 36.9 Million USD | 133.54% |
| 1991 | 15.8 Million USD | 24.41% |
| 1990 | 12.7 Million USD | 33.68% |
| 1989 | 9.5 Million USD | 75.93% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 351 Thousand USD | 7.67% |
| 2024 Q1 | 326 Thousand USD | 50.93% |
| 2024 Q3 | 351 Thousand USD | 0.0% |
| 2023 Q2 | 318 Thousand USD | 11.58% |
| 2023 Q1 | 285 Thousand USD | 20.25% |
| 2023 Q4 | 216 Thousand USD | -4.0% |
| 2023 Q3 | 225 Thousand USD | -29.25% |
| 2023 FY | 1.04 Million USD | -1.32% |
| 2022 Q2 | 303 Thousand USD | 2.02% |
| 2022 Q1 | 297 Thousand USD | 14.23% |
| 2022 FY | 1.05 Million USD | -9.57% |
| 2022 Q4 | 237 Thousand USD | 7.24% |
| 2022 Q3 | 221 Thousand USD | -27.06% |
| 2021 Q2 | 312 Thousand USD | -15.68% |
| 2021 Q1 | 370 Thousand USD | -18.86% |
| 2021 FY | 1.17 Million USD | -13.78% |
| 2021 Q3 | 228 Thousand USD | -26.92% |
| 2021 Q4 | 260 Thousand USD | 14.04% |
| 2020 Q3 | 415 Thousand USD | 70.08% |
| 2020 Q4 | 456 Thousand USD | 9.88% |
| 2020 FY | 1.35 Million USD | 15.0% |
| 2020 Q1 | 242 Thousand USD | -21.17% |
| 2020 Q2 | 244 Thousand USD | 0.83% |
| 2019 Q4 | 307 Thousand USD | -6.12% |
| 2019 Q3 | 327 Thousand USD | 43.42% |
| 2019 FY | 1.18 Million USD | 11.01% |
| 2019 Q2 | 228 Thousand USD | -28.3% |
| 2019 Q1 | 318 Thousand USD | 34.18% |
| 2018 FY | 1.06 Million USD | -22.47% |
| 2018 Q1 | 326 Thousand USD | -6.86% |
| 2018 Q3 | 239 Thousand USD | -10.49% |
| 2018 Q2 | 267 Thousand USD | -18.1% |
| 2018 Q4 | 237 Thousand USD | -0.84% |
| 2017 Q2 | 337 Thousand USD | -3.44% |
| 2017 Q3 | 335 Thousand USD | -0.59% |
| 2017 Q4 | 350 Thousand USD | 4.48% |
| 2017 FY | 1.37 Million USD | -18.34% |
| 2017 Q1 | 349 Thousand USD | 139.04% |
| 2016 Q4 | 146 Thousand USD | -61.17% |
| 2016 FY | 1.67 Million USD | -21.91% |
| 2016 Q2 | 436 Thousand USD | -39.53% |
| 2016 Q3 | 376 Thousand USD | -13.76% |
| 2016 Q1 | 721 Thousand USD | -13.96% |
| 2015 Q4 | 838 Thousand USD | 293.43% |
| 2015 Q2 | 516 Thousand USD | -11.49% |
| 2015 FY | 2.15 Million USD | -9.78% |
| 2015 Q3 | 213 Thousand USD | -58.72% |
| 2015 Q1 | 583 Thousand USD | 24.57% |
| 2014 Q4 | 468 Thousand USD | -18.04% |
| 2014 Q1 | 508 Thousand USD | -64.4% |
| 2014 Q2 | 836 Thousand USD | 64.57% |
| 2014 Q3 | 571 Thousand USD | -31.7% |
| 2014 FY | 2.38 Million USD | -79.38% |
| 2013 Q1 | 4.52 Million USD | -38.79% |
| 2013 Q4 | 1.42 Million USD | -51.0% |
| 2013 Q3 | 2.91 Million USD | 8.17% |
| 2013 Q2 | 2.69 Million USD | -40.55% |
| 2013 FY | 11.55 Million USD | -67.26% |
| 2012 FY | 35.3 Million USD | -39.66% |
| 2012 Q4 | 7.39 Million USD | 3.12% |
| 2012 Q3 | 7.17 Million USD | -28.69% |
| 2012 Q2 | 10.05 Million USD | -5.76% |
| 2012 Q1 | 10.67 Million USD | -15.62% |
| 2011 Q4 | 12.65 Million USD | -13.28% |
| 2011 Q3 | 14.58 Million USD | -2.27% |
| 2011 Q2 | 14.92 Million USD | -8.65% |
| 2011 Q1 | 16.33 Million USD | -19.7% |
| 2011 FY | 58.5 Million USD | -30.7% |
| 2010 Q1 | 25.81 Million USD | -24.85% |
| 2010 FY | 84.41 Million USD | -37.26% |
| 2010 Q2 | 18.08 Million USD | -29.95% |
| 2010 Q3 | 20.17 Million USD | 11.55% |
| 2010 Q4 | 20.34 Million USD | 0.87% |
| 2009 Q4 | 34.34 Million USD | 15.88% |
| 2009 Q3 | 29.64 Million USD | -21.55% |
| 2009 Q2 | 37.78 Million USD | 14.29% |
| 2009 Q1 | 33.05 Million USD | -5.43% |
| 2009 FY | 134.54 Million USD | 3.44% |
| 2008 Q4 | 34.95 Million USD | 2.59% |
| 2008 Q3 | 34.07 Million USD | 5.52% |
| 2008 Q1 | 28.74 Million USD | -10.62% |
| 2008 Q2 | 32.29 Million USD | 12.34% |
| 2008 FY | 130.06 Million USD | 301.59% |
| 2007 Q4 | 32.15 Million USD | 150.72% |
| 2007 Q2 | 33.14 Million USD | 11.93% |
| 2007 FY | 32.38 Million USD | -71.6% |
| 2007 Q3 | -63.4 Million USD | -291.28% |
| 2007 Q1 | 29.61 Million USD | -27.81% |
| 2006 FY | 114.03 Million USD | 0.0% |
| 2006 Q4 | 41.02 Million USD | 63.55% |
| 2006 Q3 | 25.08 Million USD | 0.74% |
| 2006 Q2 | 24.89 Million USD | 8.11% |
| 2006 Q1 | 23.03 Million USD | 0.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q4 | - USD | -100.0% |
| 2005 Q3 | 20.36 Million USD | -21.69% |
| 2005 Q2 | 26 Million USD | -13.14% |
| 2005 Q1 | 29.93 Million USD | 14.92% |
| 2004 Q1 | 26.63 Million USD | 19.83% |
| 2004 FY | 103.54 Million USD | -9.87% |
| 2004 Q3 | 25.6 Million USD | -23.73% |
| 2004 Q4 | 26.05 Million USD | 1.76% |
| 2004 Q2 | 33.57 Million USD | 26.06% |
| 2003 Q3 | 21.11 Million USD | -53.37% |
| 2003 Q2 | 45.29 Million USD | 126.78% |
| 2003 Q1 | 19.97 Million USD | -52.01% |
| 2003 Q4 | 22.22 Million USD | 5.24% |
| 2003 FY | 114.88 Million USD | 227.18% |
| 2002 Q1 | 8.72 Million USD | 2.45% |
| 2002 Q2 | 10.26 Million USD | 17.65% |
| 2002 Q4 | 41.61 Million USD | 419.95% |
| 2002 Q3 | 8 Million USD | -21.99% |
| 2002 FY | 35.11 Million USD | 41.32% |
| 2001 Q4 | 8.51 Million USD | 11.73% |
| 2001 FY | 24.84 Million USD | 16.44% |
| 2001 Q1 | 6.32 Million USD | 25.94% |
| 2001 Q2 | 7.78 Million USD | 23.14% |
| 2001 Q3 | 7.61 Million USD | -2.17% |
| 2000 Q4 | 5.02 Million USD | -12.05% |
| 2000 Q1 | 6.84 Million USD | 42.7% |
| 2000 Q2 | 5.76 Million USD | -15.87% |
| 2000 Q3 | 5.71 Million USD | -0.9% |
| 2000 FY | 21.33 Million USD | 42.26% |
| 1999 Q2 | 4.4 Million USD | 25.71% |
| 1999 FY | 15 Million USD | 0.0% |
| 1999 Q3 | 3.9 Million USD | -11.36% |
| 1999 Q4 | 4.8 Million USD | 23.08% |
| 1999 Q1 | 3.5 Million USD | -12.5% |
| 1998 Q3 | 3.1 Million USD | -27.91% |
| 1998 FY | 15 Million USD | 6.38% |
| 1998 Q2 | 4.3 Million USD | 13.16% |
| 1998 Q4 | 4 Million USD | 29.03% |
| 1998 Q1 | 3.8 Million USD | 8.57% |
| 1997 Q1 | 3.4 Million USD | -2.86% |
| 1997 Q2 | 3.5 Million USD | 2.94% |
| 1997 FY | 14.1 Million USD | -22.53% |
| 1997 Q4 | 3.5 Million USD | 0.0% |
| 1997 Q3 | 3.5 Million USD | 0.0% |
| 1996 Q2 | 4.8 Million USD | 6.67% |
| 1996 Q1 | 4.5 Million USD | 2.27% |
| 1996 Q4 | 3.5 Million USD | -5.41% |
| 1996 FY | 18.2 Million USD | -19.82% |
| 1996 Q3 | 3.7 Million USD | -22.92% |
| 1995 FY | 22.7 Million USD | -29.5% |
| 1995 Q3 | 4.5 Million USD | -15.09% |
| 1995 Q2 | 5.3 Million USD | 1.92% |
| 1995 Q1 | 5.2 Million USD | -16.13% |
| 1995 Q4 | 4.4 Million USD | -2.22% |
| 1994 Q1 | 7.4 Million USD | -10.84% |
| 1994 Q2 | 7.8 Million USD | 5.41% |
| 1994 Q3 | 5.9 Million USD | -24.36% |
| 1994 Q4 | 6.2 Million USD | 5.08% |
| 1994 FY | 32.2 Million USD | -8.52% |
| 1993 Q4 | 8.3 Million USD | -3.49% |
| 1993 Q1 | 9.6 Million USD | 134.15% |
| 1993 Q2 | 9 Million USD | -6.25% |
| 1993 FY | 35.2 Million USD | -4.61% |
| 1993 Q3 | 8.6 Million USD | -4.44% |
| 1992 Q4 | 4.1 Million USD | -45.33% |
| 1992 Q1 | 7.3 Million USD | -47.86% |
| 1992 FY | 36.9 Million USD | 133.54% |
| 1992 Q2 | 10.9 Million USD | 49.32% |
| 1992 Q3 | 7.5 Million USD | -31.19% |
| 1991 Q3 | 4.6 Million USD | -2.13% |
| 1991 FY | 15.8 Million USD | 24.41% |
| 1991 Q1 | 4.3 Million USD | 0.0% |
| 1991 Q2 | 4.7 Million USD | 9.3% |
| 1991 Q4 | 14 Million USD | 204.35% |
| 1990 Q2 | -13.5 Million USD | 0.0% |
| 1990 Q3 | - USD | 100.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 FY | 12.7 Million USD | 33.68% |
| 1989 Q3 | - USD | 100.0% |
| 1989 Q4 | - USD | 0.0% |
| 1989 Q2 | -10.5 Million USD | 0.0% |
| 1989 Q1 | - USD | 0.0% |
| 1989 FY | 9.5 Million USD | 75.93% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 21.823% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 79.294% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 96.467% |
| Nascent Biotech, Inc. | 2.22 Million USD | 53.181% |
| Rebus Holdings, Inc. | 664 Thousand USD | -57.229% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 97.198% |
| Qrons Inc. | 643.67 Thousand USD | -62.193% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -167.991% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.182% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -151.276% |
| Skye Bioscience, Inc. | 13.54 Million USD | 92.294% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.797% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 78.771% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -298.89% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.781% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 64.2% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 30.488% |
| Mesoblast Limited | 5.9 Million USD | 82.311% |
| Marizyme, Inc. | 19.23 Million USD | 94.574% |
| Genus plc | 147.7 Million USD | 99.293% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 88.108% |
| Pharming Group N.V. | 225.49 Million USD | 99.537% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 49.041% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 22.179% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 87.481% |
| ContraFect Corporation | 56.88 Million USD | 98.165% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 76.319% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 29.4% |
| IMV Inc. | 37.7 Million USD | 97.231% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 62.585% |
| MultiCell Technologies, Inc. | 567.42 USD | -183890.695% |
| ONE Bio Corp. | 6.44 Million USD | 83.799% |
| Accustem Sciences Inc. | 3.74 Million USD | 72.133% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.785% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -96.255% |
| Q BioMed Inc. | 3.43 Million USD | 69.621% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 95.776% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 60.267% |
| Biomind Labs Inc. | 994.18 Thousand USD | -5.011% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.949% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 40.671% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 84.46% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 44.003% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 4276.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 93.479% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 43.109% |
| GB Sciences, Inc. | 1.42 Million USD | 26.505% |
| Alpha Cognition Inc. | 9.7 Million USD | 89.243% |
| HST Global, Inc. | 140.9 Thousand USD | -640.914% |
| CSL Limited | 3.44 Billion USD | 99.97% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 7.193% |
| Halberd Corporation | 74.84 Thousand USD | -1294.939% |
| Enzolytics Inc. | 2.17 Million USD | 52.099% |
| Agentix Corp. | 1.37 Million USD | 23.893% |
| Resverlogix Corp. | 12.71 Million USD | 91.787% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 71.403% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.932% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 56.589% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 33.897% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 69.339% |
| AVAX Technologies, Inc. | 7.31 Million USD | 85.719% |
| Zenith Capital Corp. | 8.94 Million USD | 88.326% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.874% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -5892.767% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 57.48% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -508.714% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 45.651% |
| Kadimastem Ltd | 2.41 Million USD | 56.683% |
| Helix BioMedix, Inc. | 1.97 Million USD | 47.06% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 90.393% |
| BioStem Technologies, Inc. | 22.97 Million USD | 95.456% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -475.254% |
| LadRx Corporation | 3.81 Million USD | 72.611% |
| Cell Source, Inc. | 4.32 Million USD | 75.863% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -13.047% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -13.047% |
| NovAccess Global Inc. | 2.46 Million USD | 57.677% |
| Affymax, Inc. | 39.38 Million USD | 97.349% |
| Itoco Inc. | 919.14 Thousand USD | -13.584% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 75.368% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 6.702% |
| Mobile Lads Corp. | 554.54 Thousand USD | -88.262% |
| CytoDyn Inc. | 18.05 Million USD | 94.219% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -4047.96% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -374.377% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 26.468% |
| SYBLEU INC | 160.87 Thousand USD | -548.947% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 42.521% |
| International Stem Cell Corporation | 5.27 Million USD | 80.194% |
| Bioxytran, Inc. | 3.82 Million USD | 72.671% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1883.207% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -5031.986% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 97.121% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 35.476% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -41.88% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 66.442% |
| Neutra Corp. | 243.82 Thousand USD | -328.183% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 94.02% |
| PureTech Health plc | 144.59 Million USD | 99.278% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 94.905% |
| IXICO plc | 4.7 Million USD | 77.82% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 88.132% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.113% |
| CSL Limited | 3.89 Billion USD | 99.973% |
| Cellectis S.A. | 97.32 Million USD | 98.927% |